Fulcrum Therapeutics announced the discontinuation of its sickle cell disease drug, pociredir, after the FDA raised serious safety concerns linked to a high rate of secondary blood cancers observed with a similar drug. This led to no viable regulatory path for further development, causing the company's stock to drop 51% in one day. Kaplan Fox & Kilsheimer LLP is now investigating potential securities violations related to this event, inviting affected investors to come forward. This development highlights significant regulatory risks in drug development for rare diseases and may impact investor confidence in the company.
Pinterest director Benjamin Silbermann recently sold 93,750 shares of the company, generating approximately $1.8 million from the transaction. This sale could indicate a personal financial move or a strategic decision, but it may attract investor att...
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Greenbrier Companies strongly rejects allegations by UTLX Manufacturing, a Berkshire Hathaway subsidiary, which filed petitions for antidumping and countervailing duties on certain railway tank cars and parts. Greenbrier asserts it continues to manuf...
